NCT06958926

A Translational Study for Locoregional Recurrence of T4 Colon Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: National Taiwan University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The outcome of T4 locally advanced colon cancer is poor when locoregional recurrence occurred. Previous studies had showed that the aggravation of T4 colon cancer is higher than N-positive colon cancer, contributing to staging paradox that outcomes of stage IIB/C are poorer than stage IIIA colon cancer and higher locoregional recurrence of stage IIB/C colon cancer. The phenomenon cannot be explained by radicality, lymph node harvested and adjuvant chemotherapy administration. To elucidate the cancerous aggravation of T4 colon cancer, the investigators should dive into the clinicopathology, metastatic mechanism and cancer biology. The investigators hypothesize that peritoneal spreading can be one of the metastatic routes of T4 colon cancer; however, few studies have addressed the finding and deserved investigation. Previous research have found that serum epigenetic alterations and cell-free DNA can serve as a prognostic marker for stage II/III colon cancer. Therefore, the aim of this study is (1) to explore the role of ascites cfDNA as a potential biomolecular marker for locoregional recurrence; (2) to identify the risk factors of locoregional recurrence for T4 colon cancer by correlating biomolecular markers between clinicopathology, epigenomic alterations in blood and ascites.

Conditions

• T4 Colorectal Cancer
• Colorectal Cancer Stage III
• Colorectal Cancer Stage II

Interventions

Type	Name	Description
PROCEDURE	Radical surgery for colon and rectum cancer	Radical surgery for colon and rectum cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.
PROCEDURE	Radical surgery for colorectal cancer	Radical surgery for colorectal cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.

Timeline

• Start date: 2025-05-14
• Primary completion: 2025-12-31
• Completion: 2028-12-31
• First posted: 2025-05-06
• Last updated: 2025-05-25

Locations

1 site across 1 country: Taiwan